Interferon-alpha therapy in HBeAg-negative chronic hepatitis B: a long-term prospective study from north-western Greece
Φόρτωση...
Ημερομηνία
Συγγραφείς
Baltayiannis, G.
Katsanos, K.
Karayiannis, P.
Tsianos, E. V.
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer-reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Aliment Pharmacol Ther
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
AIMS: To determine the long-term response to interferon-alpha therapy in patients with hepatitis B e antigen-negative chronic hepatitis B, and the factors independently associated with response and survival. METHODS: Sixty-three patients with documented hepatitis B e antigen-negative chronic hepatitis B treated with interferon-alpha for a year were followed-up for a period of 6 years. RESULTS: Sustained biochemical and virological response was seen in 34.91% and 33.33% of patients at 6 and 12 months of follow-up, respectively, and histological improvement in 54.5% of sustained responders compared with non-responders (7.1%, P = 0.004, chi-squared test), at 6 months of follow-up. Multivariate analysis showed that patients with hepatitis B virus-DNA levels at 6 months of treatment <10,000 copies/mL had a low probability of relapse, compared with those with levels >10 000 copies/mL (P = 0.032). Age (>65 years) and hepatitis B virus-DNA level at 6 months of treatment (>10,000 copies/mL) were the independent factors for disease progression and survival (P = 0.041 and P = 0.044 respectively). At 6 years, a sustained response was still present in 19.04% of patients and 4.8% of them had developed anti-HBs. CONCLUSION: Hepatitis B virus-DNA monitoring by quantitative polymerase chain reaction at 6 months of treatment may allow for early prediction of response to interferon-alpha, and may serve as an indicator of disease progression in the future.
Περιγραφή
Λέξεις-κλειδιά
Adolescent, Adult, Aged, Antiviral Agents/*therapeutic use, Female, Greece, Hepatitis B e Antigens, Hepatitis B, Chronic/*drug therapy, Humans, Interferon-alpha/*therapeutic use, Male, Middle Aged, Prospective Studies, Recurrence, Survival Analysis, Treatment Outcome
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
http://www.ncbi.nlm.nih.gov/pubmed/16886919
http://onlinelibrary.wiley.com/store/10.1111/j.1365-2036.2006.03008.x/asset/j.1365-2036.2006.03008.x.pdf?v=1&t=h0uldm7g&s=b01af0fb4f0e9890d991b587d10c864d86636f7b
http://onlinelibrary.wiley.com/store/10.1111/j.1365-2036.2006.03008.x/asset/j.1365-2036.2006.03008.x.pdf?v=1&t=h0uldm7g&s=b01af0fb4f0e9890d991b587d10c864d86636f7b
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής